@misc{oai:repo.qst.go.jp:00085007,
 author = {Honoka, Obata and Honoka, Obata},
 month = {Feb},
 note = {Recently, targeted radionuclide therapy (TRT) with radionuclide-derived short-range radiation has been growing rapidly. Due to their nano-scale range (2–500 nm), Auger electrons (Auger e−) have the potential to induce physiochemical damage to biomolecules smaller than a single cell, meaning that it is necessary to transport Auger e−-emitting radiopharmaceuticals to cellular regions that are sensitive to Auger e−. DNA is a prime target of Auger e− TRT; however, proper drug design has remained elusive. The DNA-damaging effect of Auger e− is maximized by an efficient interaction with DNA when Auger e− emitters are as close as possible to DNA. In this regard, radio-Pt is suitable for Auger e− TRT targeting DNA efficiently because of the unique DNA-binding ability of Pt. We have established a novel production method of no-carrier–added radio-Pt (n.c.a. 191Pt emitting Auger electrons) and developed labeling methods for n.c.a. 191Pt. In this presentation, I will introduce the series of research on 191Pt from the development of 191Pt-labeled agents to their biological evaluation., On the Horizon: Novel Isotopes and Future Leaders},
 title = {Development of radio-Pt-based agents for targeted Auger electron therapy ~from radionuclide production to radio-labeling and biological evaluation},
 year = {2022}
}